SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Cooke, E.D.
Right arrow Articles by Kirby, J.D.T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cooke, E.D.
Right arrow Articles by Kirby, J.D.T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Raynaud's Disease
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CL115,347, an Analogue of Prostaglandin E2

Peripheral Circulatory Effects of Single Ascending Doses Administered Transdermally in Normal Subjects and in Patients with Raynaud's Phenomenon

E.D. Cooke

Departments of Medical Electronics and Dermatology, St. Bartholomew's Hospital, London, England

Sally A. Bowcock

Departments of Medical Electronics and Dermatology, St. Bartholomew's Hospital, London, England

C.J. Watkins

Departments of Medical Electronics and Dermatology, St. Bartholomew's Hospital, London, England

M.H.A. Rustin

Departments of Medical Electronics and Dermatology, St. Bartholomew's Hospital, London, England

J.D.T. Kirby

Departments of Medical Electronics and Dermatology, St. Bartholomew's Hospital, London, England

The beneficial effects of intra-arterial or intravenous infusion of the prostanoid products of anachridonic acid, PGE and prostacyclin (PGI2) are well documented. More recently an analogue of PGE2, (CL 115,347, American Cynamid Co.) has become available. This substance is absorbed transdermally from a patch placed on the skin.

In a placebo-controlled trial the vasodilatory effect of single incremental dosage, 500 mcg, 1000 mcg and 1500 mcg, was measured in a temperature-/humidity controlled laboratory in normal subjects and in patients with primary and secondary Raynaud's phenomenon. The optimal dosage proved to be 1000 mcg; the effect may last for 84 hours; higher dosage may be associated with a "steal" phenomenon.

Angiology, Vol. 36, No. 12, 867-871 (1985)
DOI: 10.1177/000331978503601205
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement